T2381
|
|
|
CDK
|
Abemaciclib (LY2835219) 是一种 CDK4/6 的双重抑制剂 (IC50=2/10 nM),具有选择性和特异性。Abemaciclib 具有抗肿瘤活性,被用于治疗晚期或转移性乳腺癌。 |
T3111
|
|
|
CDK
|
Abemaciclib methanesulfonate (LY2835219) 是一种选择性的CDK4/6抑制剂,能够抑制 CDK4/CDK6 的活性,IC50分别为 2 nM 和 10 nM。 |
T10220
|
|
|
CDK
|
Abemaciclib Metabolites M2 is a metabolite of abemaciclib, acts as a potent CDK4 and CDK6 inhibitor (IC50s: 1-3 nM) with anti-cancer activity. |
T10738
|
|
|
CDK
|
Abemaciclib metabolite M20 (CDK4/6-IN-4) 是 Abemaciclib 的活性代谢物。 Abemaciclib metabolite M20 是一种特异性 CDK4/6 抑制剂,可用于癌症治疗的相关研究。 |
T73909
|
|
|
Ligands for Target Protein for PROTAC
|
Abemaciclibmetabolite M18 (LSN3106729) 是一种CDK抑制剂,具有抗肿瘤活性。作为Abemaciclib的代谢物,Abemaciclibmetabolite M18 能与CRBN配体结合,用于设计PROTAC CDK4/6降解剂。 |
T36967
|
|
|
|
LSN3106729 hydrochloride, the metabolite of Abemaciclib , is a CDK inhibitor with antitumor activity. LSN3106729 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1].
[1]. Edward S. Kim, et al. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. [2]. Nathanael Gray, et al. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use. WO2017185031A1. |